FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Janne Backman

Research Profile

Procedures

Concepts & Ideas

Physiology

Drug Interactions

Chemicals & Drugs

Anatomy

Microsomes, Liver

Co-author Network

Publications

TOP 3
Mikko T Holmberg; Lotta Joutsi-Korhonen; Riitta Lassila; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi; Aleksi Tornio; Janne T Backman
Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects.
Tuija Tapaninen; Janne T Backman; T Karonen; Pertti J Neuvonen; Mikko Niemi
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Anne M Filppula; Jouko Laitila; Mikko Neuvonen; Pertti J Neuvonen; Janne T Backman
Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Janne Backman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mikko T Holmberg; Lotta Joutsi-Korhonen; Riitta Lassila; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi; Aleksi Tornio; Janne T Backman
Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects.
British journal of clinical pharmacology 2013;75(6):1488-96.
2013: Tuija Tapaninen; Janne T Backman; T Karonen; Pertti J Neuvonen; Mikko Niemi
SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Pharmacogenetics and genomics 2013;23(1):19-24.
2013: Anne M Filppula; Jouko Laitila; Mikko Neuvonen; Pertti J Neuvonen; Janne T Backman
Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(1):50-9.
2012: E K Tarkiainen; Matthias Schwab; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Clinical pharmacology and therapeutics 2012;92(1):68-71.
2012: Aleksi Tornio; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
Trends in pharmacological sciences 2012;33(6):312-22.
2012: J Honkalammi; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
Clinical pharmacology and therapeutics 2012;91(5):846-55.
2012: T Karonen; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
European journal of clinical pharmacology 2012;68(5):681-8.
2012: Xiaoqiang Xiang; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings.
Basic & clinical pharmacology & toxicology 2012;110(3):245-52.
2012: Stefanie Hennig; Andrew C Hooker; Kalle Hoppu; Janne T Backman; Samuel Fanta; Joakim Nyberg; Mats O Karlsson
Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin.
Journal of clinical pharmacology 2012;52(3):347-60.
2011: Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
European journal of clinical pharmacology 2011;67(11):1159-67.
2011: Johanna Honkalammi; Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1977-86.
2011: Anne M Filppula; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):904-11.
2011: J Honkalammi; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
Clinical pharmacology and therapeutics 2011;89(4):579-86.
2011: Tuija Tapaninen; Janne T Backman; Kaisa J Kurkinen; Pertti J Neuvonen; Mikko Niemi
Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Journal of clinical pharmacology 2011;51(3):359-67.
2011: T Karonen; Pertti J Neuvonen; Janne T Backman
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
European journal of clinical pharmacology 2011;67(2):151-5.
2010: T Karonen; A Filppula; Jouko Laitila; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Clinical pharmacology and therapeutics 2010;88(2):223-30.
2010: Samuel Fanta; Siv Jönsson; Mats O Karlsson; Mikko Niemi; Christer Holmberg; Kalle Hoppu; Janne T Backman
Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.
Journal of clinical pharmacology 2010;50(5):581-97.
2009: Janne T Backman; Johanna Honkalammi; Mikko Neuvonen; Kaisa J Kurkinen; Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(12):2359-66.
2009: Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
British journal of clinical pharmacology 2009;68(2):207-13.
2009: Murali Shyamsundar; Scott T W McKeown; Cecilia M O'Kane; Thelma R Craig; Vanessa Brown; David R Thickett; Michael A Matthay; Clifford Taggart; Janne T Backman; J Stuart Elborn; Daniel F McAuley
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.
American journal of respiratory and critical care medicine 2009;179(12):1107-14.
2009: Xiaoqiang Xiang; Yi Han; Mikko Neuvonen; Marja K Pasanen; Annikka Kalliokoski; Janne T Backman; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Pharmacogenetics and genomics 2009;19(6):447-57.
2008: Annikka Kalliokoski; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Pharmacogenetics and genomics 2008;18(11):937-42.
2008: A Kalliokoski; Janne T Backman; K J Kurkinen; Pertti J Neuvonen; Mikko Niemi
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Clinical pharmacology and therapeutics 2008;84(4):488-96.
2008: Aleksi Tornio; Mikko Niemi; Mikko Neuvonen; Jouko Laitila; A Kalliokoski; Pertti J Neuvonen; Janne T Backman
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Clinical pharmacology and therapeutics 2008;84(3):403-11.
2008: Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Basic & clinical pharmacology & toxicology 2008;103(2):157-65.
2008: Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
European journal of clinical pharmacology 2008;64(5):511-9.
2008: Samuel Fanta; Mikko Niemi; Siv Jönsson; Mats O Karlsson; Christer Holmberg; Pertti J Neuvonen; Kalle Hoppu; Janne T Backman
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Pharmacogenetics and genomics 2008;18(2):77-90.
2008: Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Clinical pharmacokinetics 2008;47(7):463-74.
2008: Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
European journal of clinical pharmacology 2008;64(1):17-24.
2008: Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):73-80.
2007: S Fanta; S Jönsson; Janne T Backman; M O Karlsson; Kalle Hoppu
Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.
British journal of clinical pharmacology 2007;64(6):772-84.
2007: Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
European journal of clinical pharmacology 2007;63(9):829-36.
2007: Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
Clinical pharmacology and therapeutics 2007;81(6):833-9.
2007: Aleksi Tornio; Mikko Niemi; Pertti J Neuvonen; Janne T Backman
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
European journal of clinical pharmacology 2007;63(5):463-9.
2006: Pertti J Neuvonen; Mikko Niemi; Janne T Backman
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Clinical pharmacology and therapeutics 2006;80(6):565-81.
2006: Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(12):2091-6.
2006: Mikko Niemi; Katja A Arnold; Janne T Backman; Marja K Pasanen; Ute Gödtel-Armbrust; Leszek Wojnowski; Uli Zanger; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö; Thomas Lang
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and genomics 2006;16(11):801-8.
2006: Janne T Backman; Marjo J Karjalainen; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
British journal of clinical pharmacology 2006;62(3):345-57.
2006: Janne T Backman; Lauri I Kajosaari; Mikko Niemi; Pertti J Neuvonen
Cyclosporine A increases plasma concentrations and effects of repaglinide.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6(9):2221-2.
2006: Aleksi Tornio; Pertti J Neuvonen; Janne T Backman
The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
European journal of clinical pharmacology 2006;62(8):645-51.
2006: Tiina Jaakkola; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Basic & clinical pharmacology & toxicology 2006;99(1):44-51.
2006: Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Mikko Niemi; Pertti J Neuvonen
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
European journal of clinical pharmacology 2006;62(7):503-9.
2006: Mikko Niemi; Aleksi Tornio; Marja K Pasanen; Hanna Fredrikson; Pertti J Neuvonen; Janne T Backman
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
European journal of clinical pharmacology 2006;62(6):463-72.
2006: Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
European journal of clinical pharmacology 2006;62(6):451-61.
2006: Marja K Pasanen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
European journal of clinical pharmacology 2006;62(6):409-15.
2006: Lauri I Kajosaari; Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Clinical pharmacology and therapeutics 2006;79(3):231-42.
2006: Lauri I Kajosaari; Tiina Jaakkola; Pertti J Neuvonen; Janne T Backman
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
European journal of clinical pharmacology 2006;62(3):217-23.
2006: Aino Lepäntalo; Jussi Mikkelsson; Julio C Reséndiz; Leena Viiri; Janne T Backman; Esko Kankuri; Pekka J Karhunen; Riitta Lassila
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
Thrombosis and haemostasis 2006;95(2):253-9.
2006: Marika T Granfors; Jun-Sheng Wang; Lauri I Kajosaari; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Basic & clinical pharmacology & toxicology 2006;98(1):79-85.
2006: Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Effect of rifampicin on the pharmacokinetics of pioglitazone.
British journal of clinical pharmacology 2006;61(1):70-8.
2005: Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Effect of itraconazole on the pharmacokinetics of atenolol.
Basic & clinical pharmacology & toxicology 2005;97(6):395-8.
2005: Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Clinical pharmacology and therapeutics 2005;78(4):400-11.
2005: Lauri I Kajosaari; Mikko Niemi; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Cyclosporine markedly raises the plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2005;78(4):388-99.
2005: Lauri I Kajosaari; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Basic & clinical pharmacology & toxicology 2005;97(4):249-56.
2005: Janne T Backman; Harri Luurila; Mikko Neuvonen; Pertti J Neuvonen
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Clinical pharmacology and therapeutics 2005;78(2):154-67.
2005: Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
British journal of clinical pharmacology 2005;60(2):208-17.
2005: Aleksi Tornio; Marja K Pasanen; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Basic & clinical pharmacology & toxicology 2005;97(2):104-8.
2005: Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B S Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Clinical pharmacology and therapeutics 2005;77(6):468-78.
2005: Tiina Jaakkola; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Clinical pharmacology and therapeutics 2005;77(5):404-14.
2005: Mikko Niemi; Pertti J Neuvonen; ute hofmann; Janne T Backman; Matthias Schwab; Dieter Lütjohann; Klaus Von Bergmann; Michel Eichelbaum; Kari T Kivistö
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenetics and genomics 2005;15(5):303-9.
2005: Samuel Fanta; Janne T Backman; Paula Seikku; Christer Holmberg; Kalle Hoppu
Cyclosporine A monitoring--how to account for twice and three times daily dosing.
Pediatric nephrology (Berlin, Germany) 2005;20(5):591-6.
2005: Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.
British journal of clinical pharmacology 2005;59(4):433-9.
2004: Marika T Granfors; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Clinical pharmacology and therapeutics 2004;76(6):598-606.
2004: Lauri I Kajosaari; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
British journal of clinical pharmacology 2004;58(4):390-6.
2004: Mikko Niemi; Janne T Backman; Pertti J Neuvonen
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Clinical pharmacology and therapeutics 2004;76(3):239-49.
2004: Mikko Niemi; Elke Schaeffeler; Thomas Lang; Martin F Fromm; Mikko Neuvonen; Carl Kyrklund; Janne T Backman; Reinhold Kerb; Matthias Schwab; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004;14(7):429-40.
2004: Marika T Granfors; Janne T Backman; Mikko Neuvonen; Jouni Ahonen; Pertti J Neuvonen
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Clinical pharmacology and therapeutics 2004;75(4):331-41.
2004: Mikko Niemi; Lauri I Kajosaari; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
British journal of clinical pharmacology 2004;57(4):441-7.
2004: Marika T Granfors; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.
British journal of clinical pharmacology 2004;57(3):349-53.
2004: Carl Kyrklund; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.
British journal of clinical pharmacology 2004;57(2):181-7.
2003: Mikko Niemi; Julian B S Leathart; Mikko Neuvonen; Janne T Backman; Ann K Daly; Pertti J Neuvonen
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2003;74(4):380-7.
2003: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
British journal of clinical pharmacology 2003;56(4):427-32.
2003: Mikko Niemi; Janne T Backman; Marika T Granfors; Jouko Laitila; Mikko Neuvonen; Pertti J Neuvonen
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Diabetologia 2003;46(10):1319-23.
2003: Mikko Niemi; Mikko Neuvonen; Laura Juntti-Patinen; Janne T Backman; Pertti J Neuvonen
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Clinical pharmacology and therapeutics 2003;74(1):25-31.
2003: Carl Kyrklund; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
Clinical pharmacology and therapeutics 2003;73(6):538-44.
2003: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Diabetologia 2003;46(3):347-51.
2003: Jari J Lilja; Janne T Backman; Jouko Laitila; Harri Luurila; Pertti J Neuvonen
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.
Clinical pharmacology and therapeutics 2003;73(3):192-8.
2003: Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Pharmacokinetic interactions with rifampicin : clinical relevance.
Clinical pharmacokinetics 2003;42(9):819-50.
2002: Janne T Backman; Carl Kyrklund; Mikko Neuvonen; Pertti J Neuvonen
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Clinical pharmacology and therapeutics 2002;72(6):685-91.
2002: Jun-Sheng Wang; Mikko Neuvonen; Xia Wen; Janne T Backman; Pertti J Neuvonen
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1352-6.
2002: Bernhard Sperker; Thomas E Mürdter; Janne T Backman; Peter Fritz; Heyo K Kroemer
Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
Life sciences 2002;71(13):1547-57.
2002: Jun-Sheng Wang; Xia Wen; Janne T Backman; Pertti J Neuvonen
Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
The Journal of pharmacology and experimental therapeutics 2002;302(1):43-9.
2002: Xia Wen; Jun-Sheng Wang; Janne T Backman; Jouko Laitila; Pertti J Neuvonen
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):631-5.
2002: Thomas E Mürdter; Godehard Friedel; Janne T Backman; Monika McClellan; Monika Schick; Manfred Gerken; Klaus Bosslet; Peter Fritz; Heikki Toomes; Heyo K Kroemer; Bernhard Sperker
Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.
The Journal of pharmacology and experimental therapeutics 2002;301(1):223-8.
2002: Xia Wen; Jun-Sheng Wang; Pertti J Neuvonen; Janne T Backman
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
European journal of clinical pharmacology 2002;57(11):799-804.
2001: Xia Wen; Jun-Sheng Wang; Kari T Kivistö; Pertti J Neuvonen; Janne T Backman
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
British journal of clinical pharmacology 2001;52(5):547-53.
2001: Xia Wen; Jun-Sheng Wang; Janne T Backman; Kari T Kivistö; Pertti J Neuvonen
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(11):1359-61.
2001: K Villikka; T Varis; Janne T Backman; Pertti J Neuvonen; Kari T Kivistö
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.
European journal of clinical pharmacology 2001;57(6-7):457-60.
2001: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Kari T Kivistö
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
Clinical pharmacology and therapeutics 2001;69(6):400-6.
2001: Carl Kyrklund; Janne T Backman; Kari T Kivistö; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
Clinical pharmacology and therapeutics 2001;69(5):340-5.
2001: Kari T Kivistö; Jun-Sheng Wang; Janne T Backman; Leena Nyman; Päivi Taavitsainen; Markku Anttila; Pertti J Neuvonen
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
European journal of clinical pharmacology 2001;57(1):37-42.
2001: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Kari T Kivistö
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;69(4):194-200.
2000: Carl Kyrklund; Janne T Backman; Kari T Kivistö; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Clinical pharmacology and therapeutics 2000;68(6):592-7.
2000: Mikko Niemi; Kari T Kivistö; Janne T Backman; Pertti J Neuvonen
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
British journal of clinical pharmacology 2000;50(6):591-5.
2000: Jun-Sheng Wang; Janne T Backman; Kari T Kivistö; Pertti J Neuvonen
Effects of metronidazole on midazolam metabolism in vitro and in vivo.
European journal of clinical pharmacology 2000;56(8):555-9.
2000: Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen; Kari T Kivistö
Rifampin decreases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2000;68(5):495-500.
2000: T Varis; Kari T Kivistö; Janne T Backman; Pertti J Neuvonen
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Clinical pharmacology and therapeutics 2000;68(5):487-94.
2000: Jari J Lilja; Kari T Kivistö; Janne T Backman; Pertti J Neuvonen
Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life.
European journal of clinical pharmacology 2000;56(5):411-5.
2000: Janne T Backman; Carl Kyrklund; Kari T Kivistö; Jun-Sheng Wang; Pertti J Neuvonen
Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Clinical pharmacology and therapeutics 2000;68(2):122-9.
2000: Jun-Sheng Wang; Janne T Backman; Päivi Taavitsainen; Pertti J Neuvonen; Kari T Kivistö
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(8):959-65.
2000: T Kantola; Janne T Backman; Mikko Niemi; Kari T Kivistö; Pertti J Neuvonen
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
European journal of clinical pharmacology 2000;56(3):225-9.
2000: Janne T Backman; J Mäenpää; Donna Belle; Steven A Wrighton; Kari T Kivistö; Pertti J Neuvonen
Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Clinical pharmacology and therapeutics 2000;67(4):382-90.
2000: T Varis; Janne T Backman; Kari T Kivistö; Pertti J Neuvonen
Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Clinical pharmacology and therapeutics 2000;67(3):215-21.
1999: Jun-Sheng Wang; Janne T Backman; Xia Wen; Päivi Taavitsainen; Pertti J Neuvonen; Kari T Kivistö
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Pharmacology & toxicology 1999;85(5):201-5.
1999: Kari T Kivistö; Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.
Clinical pharmacology and therapeutics 1999;66(5):448-53.
1999: Janne T Backman; Isabel Siegle; Uli Zanger; Peter Fritz
Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue.
The Histochemical journal 1999;31(10):645-9.
1999: Jun-Sheng Wang; Xia Wen; Janne T Backman; Päivi Taavitsainen; Pertti J Neuvonen; Kari T Kivistö
Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Pharmacology & toxicology 1999;85(4):157-61.
1999: Janne T Backman; Jun-Sheng Wang; X Wen; Kari T Kivistö; Pertti J Neuvonen
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.
Clinical pharmacology and therapeutics 1999;66(4):401-7.
1999: T Varis; Kari T Kivistö; Janne T Backman; Pertti J Neuvonen
Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
Pharmacology & toxicology 1999;85(1):29-32.
1998: Jari J Lilja; Kari T Kivistö; Janne T Backman; TS Lamberg; Pertti J Neuvonen
Grapefruit juice substantially increases plasma concentrations of buspirone.
Clinical pharmacology and therapeutics 1998;64(6):655-60.
1998: Janne T Backman; Isabel Siegle; Peter Fritz
Immunohistochemical localization of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint disease.
Virchows Archiv : an international journal of pathology 1998;433(2):153-60.
1998: Janne T Backman; Kari T Kivistö; Klaus T Olkkola; Pertti J Neuvonen
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
European journal of clinical pharmacology 1998;54(1):53-8.
1998: Isabel Siegle; T Klein; Janne T Backman; JG Saal; R M Nüsing; Peter Fritz
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Arthritis and rheumatism 1998;41(1):122-9.
1997: Bernhard Sperker; Janne T Backman; Heyo K Kroemer
The role of beta-glucuronidase in drug disposition and drug targeting in humans.
Clinical pharmacokinetics 1997;33(1):18-31.
1997: K Villikka; Kari T Kivistö; Janne T Backman; Klaus T Olkkola; Pertti J Neuvonen
Triazolam is ineffective in patients taking rifampin.
Clinical pharmacology and therapeutics 1997;61(1):8-14.
1996: Janne T Backman; Klaus T Olkkola; Matti Ojala; H Laaksovirta; Pertti J Neuvonen
Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.
Epilepsia 1996;37(3):253-7.
1996: Janne T Backman; Klaus T Olkkola; Pertti J Neuvonen
Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Clinical pharmacology and therapeutics 1996;59(1):7-13.
1995: Janne T Backman; Klaus T Olkkola; Pertti J Neuvonen
Azithromycin does not increase plasma concentrations of oral midazolam.
International journal of clinical pharmacology and therapeutics 1995;33(6):356-9.
1994: K Aranko; Harri Luurila; Janne T Backman; Pertti J Neuvonen; Klaus T Olkkola
The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone.
British journal of clinical pharmacology 1994;38(4):363-7.
1994: Klaus T Olkkola; Janne T Backman; Pertti J Neuvonen
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.
Clinical pharmacology and therapeutics 1994;55(5):481-5.
1994: Janne T Backman; Klaus T Olkkola; K Aranko; Jaakko-Juhani Himberg; Pertti J Neuvonen
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
British journal of clinical pharmacology 1994;37(3):221-5.
1994: Janne T Backman; K Aranko; Jaakko-Juhani Himberg; Klaus T Olkkola
A pharmacokinetic interaction between roxithromycin and midazolam.
European journal of clinical pharmacology 1994;46(6):551-5.